UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 多発性骨髄腫における自家造血細胞移植 autologous hematopoietic cell transplantation in multiple myeloma

English Journal

A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas.

Hartmann JT, Horger M, Kluba T, Königsrainer A, de Zwart P, von Weyhern CH, Eckert F, Budach W, Bokemeyer C.SourceMedical Oncology, Comprehensive Cancer Center North, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University, Arnold-Heller-Str. 3, Haus 27, 24105, Kiel, Germany, joerg.hartmann@uksh.de.
Investigational new drugs.Invest New Drugs.2013 Oct 4. [Epub ahead of print]
The objective was to determine the role of dose intensive induction chemotherapy in patients with soft tissue sarcomas (STS) that were considered unresectable. Treatment consisted of 2-3 cycles of doxorubicin (Dox) and ifosfamide (Ifo) followed by high dose chemotherapy with ifosfamide, carboplatin
PMID 24091981

Comparison of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in advanced stage.

Zheng C, Tang B, Yao W, Tong J, Zhu X, Song K, Geng L, Liu H, Sun Z.SourceDepartment of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China; Shandong University School of Medicine, Jinan, China.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.Biol Blood Marrow Transplant.2013 Sep 20. pii: S1083-8791(13)00407-2. doi: 10.1016/j.bbmt.2013.09.008. [Epub ahead of print]
This is the first report to present a clinical comparison of unrelated cord blood transplantation (CBT) and HLA-matched sibling allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with chronic myeloid leukemia (CML) in advanced stage (accelerated phase or blast crisis). A tot
PMID 24060407

Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma.

Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, Fenske TS, Horowitz MM, Komorowski R, Palmer J, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR.SourceDepartment of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.Biol Blood Marrow Transplant.2013 Sep;19(9):1368-73. doi: 10.1016/j.bbmt.2013.06.017. Epub 2013 Jun 24.
Engraftment syndrome (ES) is an increasingly observed and occasionally fatal complication after autologous peripheral blood stem cell transplantation (PBSCT). In this study, we demonstrate that the incidence of ES is significantly increased in patients undergoing autologous PBSCT for multiple myelom
PMID 23806770

長藤宏司
日本アフェレシス学会雑誌 31(3), 216-222, 2012-10-31
… Allogeneic peripheral blood stem cell transplantation (allo-PBSCT) has been increasingly used as an alternative to allogeneic bone marrow transplantation (allo-BMT). … Allo-PBSCT is associated with rapid hematopoietic recovery, increased incidence and severity of chronic graft-versus-host disease (GVHD), and possible increased incidence and severity of acute GVHD. …
NAID 110009543811

日野雅之
日本アフェレシス学会雑誌 31(3), 209-215, 2012-10-31
… Allogeneic peripheral blood stem cell transplantation (PBSCT) as well as allogeneic bone marrow transplantation (BMT) is a curative treatment strategy for patients with hematopoietic disorders. … PBSCT is associated with more rapid hematopoietic recovery than BMT. … Since the first unrelated PBSCT in 2011, 4 transplants have been performed. …
NAID 110009543810